Ichikawa Naomi, Yamanaka Hisashi
Institute of Rheumatology, Tokyo Women's Medical University, Japan.
Clin Calcium. 2012 Feb;22(2):215-21.
The primary goal in the treatment of rheumatoid arthritis (RA) is to maintain good quality of life by preventing joint destruction and avoiding disability. For this purpose, all patients with the diagnosis of RA should be treated by disease-modifying antirheumatic drugs (DMARDs) including biologic DMARDs and non-biologic DMARDs. All DMARDs are expected to prevent the progression of bone and cartilage destruction of RA patients from the results of in vitro research, and prevention of joint destruction is confirmed in vivo in all biologic DMARDs, but not in all non-biologic DMARDs. In this chapter, we would like to review the results of basic researches and clinical studies to demonstrate the prevention of joint destruction by non-biologic DMARDs that have been frequently used I daily practice.
类风湿关节炎（RA）治疗的主要目标是通过预防关节破坏和避免残疾来维持良好的生活质量。为此，所有确诊为RA的患者都应使用改善病情抗风湿药（DMARDs）进行治疗，包括生物DMARDs和非生物DMARDs。从体外研究结果来看，所有DMARDs都有望预防RA患者的骨和软骨破坏进展，并且在所有生物DMARDs中均已在体内证实可预防关节破坏，但并非所有非生物DMARDs都能如此。在本章中，我们将回顾基础研究和临床研究的结果，以证明日常实践中常用的非生物DMARDs对关节破坏的预防作用。
